Here is some good information on treating prostate cancer

BobsProstate

"The CARD trial shows convincingly that cabazitaxel is the preferred therapeutic option over second-line androgen-signaling inhibitors (abiraterone, enzalutamide) in patients with metastatic castration-resistant prostate cancer who had rapid disease progression while they were receiving first-line androgen-signaling inhibitors"

https://www.medscape.com/viewarticle/923146

GregP_WN

Thanks for posting the link. This is good news for prostate cancer patients.